Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - afatinib dimaleate 29.56mg equivalent to afatinib 20 mg - film coated tablet - 20 mg - active: afatinib dimaleate 29.56mg equivalent to afatinib 20 mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc titanium dioxide - giotrif is indicated as monotherapy for the treatment of patients with: locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. tumours must have epidermal growth factor receptor (egfr) mutations. locally advanced or metastatic non-small cell carcinoma of the lung of squamous histology progressing on or after platinum-based chemotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - afatinib dimaleate 44.34mg equivalent to afatinib 30 mg - film coated tablet - 30 mg - active: afatinib dimaleate 44.34mg equivalent to afatinib 30 mg excipient: colloidal silicon dioxide crospovidone hypromellose indigo carmine aluminium lake lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc titanium dioxide - giotrif is indicated as monotherapy for the treatment of patients with: locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. tumours must have epidermal growth factor receptor (egfr) mutations. locally advanced or metastatic non-small cell carcinoma of the lung of squamous histology progressing on or after platinum-based chemotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - afatinib dimaleate 59.12mg equivalent to afatinib 40 mg - film coated tablet - 40 mg - active: afatinib dimaleate 59.12mg equivalent to afatinib 40 mg excipient: colloidal silicon dioxide crospovidone hypromellose indigo carmine aluminium lake lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc titanium dioxide - giotrif is indicated as monotherapy for the treatment of patients with: locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. tumours must have epidermal growth factor receptor (egfr) mutations. locally advanced or metastatic non-small cell carcinoma of the lung of squamous histology progressing on or after platinum-based chemotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - afatinib dimaleate 73.9mg equivalent to afatinib 50 mg - film coated tablet - 50 mg - active: afatinib dimaleate 73.9mg equivalent to afatinib 50 mg excipient: colloidal silicon dioxide crospovidone hypromellose indigo carmine aluminium lake lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc titanium dioxide - giotrif is indicated as monotherapy for the treatment of patients with: locally advanced or metastatic non-squamous non-small cell carcinoma of the lung, either as first line therapy or after failure of cytotoxic chemotherapy. tumours must have epidermal growth factor receptor (egfr) mutations. locally advanced or metastatic non-small cell carcinoma of the lung of squamous histology progressing on or after platinum-based chemotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 1000mg;   - film coated tablet - 12.5mg/1000mg - active: empagliflozin 12.5mg   metformin hydrochloride 1000mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry purple 02b200006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 500mg;   - film coated tablet - 12.5mg/500mg - active: empagliflozin 12.5mg   metformin hydrochloride 500mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b20004 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 12.5mg;  ; metformin hydrochloride 850mg;   - film coated tablet - 12.5mg/850mg - active: empagliflozin 12.5mg   metformin hydrochloride 850mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b240006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 5mg;  ; metformin hydrochloride 1000mg;   - film coated tablet - 5mg/1000mg - active: empagliflozin 5mg   metformin hydrochloride 1000mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220012 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 5mg;  ; metformin hydrochloride 500mg;   - film coated tablet - 5mg/500mg - active: empagliflozin 5mg   metformin hydrochloride 500mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220011 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 5mg;  ; metformin hydrochloride 850mg;   - film coated tablet - 5mg/850mg - active: empagliflozin 5mg   metformin hydrochloride 850mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220010 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.